Orion Corporation

Pentti Nore

Sirpa Rasku

Eija Tiainen

Olli Toermaekangas

Jukka Tenhunen

Pekka Kotovuori

Arto Karjalainen

Leena Otsomaa

Tuula Koskelainen

Gerd Wohlfahrt

David Din Belle

Petteri Rummakko

Pekka Pietikäinen

Matti Vaismaa

Mikko Passiniemi

Jarmo J Pystynen

Arto J Karjalainen

Mikko Kalervo Mäkelä

Pentti T Nore

Anne M Luiro

Marko Ahlmark

Heimo O Haikala

Olli Törmäkangas

Arja Karjalainen

Jouko Levijoki

Anssi Haikarainen

Piero Pollesello

Juha Kaivola

Carola Tilgmann

Seppo Parhi

Kari L&ouml;nnberg

Petri Kaheinen

Reijo Bäckström

Ismo Ulmanen

Josef Messinger

Taina Pajunen

Mika Kauppala

Emilia Väisänen

Mikko Mäkelä

Jarmo Pystynen

Anne Luiro

Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors

CYP17 inhibitors/antiandrogens

Compounds of formula (I), wherein Ris as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. Methods of treatment and pharmaceutical dosage forms are also disclosed.

Catechol O-methyltransferase activity inhibiting compounds

Compounds of formula (I) exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. 

Pharmaceutical compounds

Therapeutically active compounds of formula (I): wherein the variables shown in formula (I) are defined in the disclosure; and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of the Na/Caexchange mechanism.

[object Object]

A method for obtaining direct dilatation of the coronary arteries by administering a therapeutically effective amount of a phospholamban inhibitor is described. Compounds which are effective in relieving the inhibitory effects of phospholamban on cardiac sarcoplasmic reticulum Ca,-ATPase are also described.

Phospholamban inhibitors and a method for increasing coronary flow

Growing community of inventors

Espoo, Finland

Eija Tiainen